rights and content material


A promising nanomedicine of DNAM was produced to scale back sclerostin and deal with osteoporosis.

An anti-sclerostin DNA aptamer layer, Aptscl56, focused bones and captured sclerostin.

MSN cores protected DNAM-attached Aptscl56 from renal filtration and degradation.

DNAM rescued osteoporosis, superior to the “gold customary” drug alendronate.


Bone-targeted drug supply to scale back systemic problems and keep adequate doses in bone tissues is the primary problem for osteoporosis therapy. Right here, we develop a novel, and easily synthesized bone-targeting nanomedicine (DNA-MSN, DNAM) containing a PEGylated dendritic mesoporous silica nanoparticle (MSN) core (~ 65 nm) and an anti-sclerostin aptamer (Aptscl56) layer, to deal with osteoporosis. The nanoparticle core protects the immobilized Aptscl56 from fast nuclease degradation and renal filtration, prolonging in vivo half-lives. The DNAM-immobilized Aptscl56 layer displays twin capabilities to direct bone-attachment of ovariectomized mice, as a result of interplay between phosphate teams in DNA aptamer Aptscl56 and bone calcium in hydroxyapatites, and to in situ seize sclerostin with picomolar affinities. Furthermore, we present DNAM considerably reverses the serum stage of sclerostin and osteoporotic bone loss to a standard stage, enhancing bone histomorphology parameters and mechanical properties within the femur, and recovering serum ranges of bone turnover markers, with out systemic toxicity. Notably, the therapeutic impact of DNAM is superior to the “gold customary” drug alendronate, and the systemic dose of DNAM-immobilized Aptscl56 is simply 25% of free Aptscl56. The current research supplies insights into the regulation of undesirable circulating biohazards and represents a promising strategy to ship nanomedicines to deal with osteoporosis.

Key phrases



Osteoporosis therapy



View full textual content

© 2022 Elsevier Ltd. All rights reserved.